Product Description
AR-201 is being developed by Aimmune Therapeutics for the desensitization of patients with hen egg allergy. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04056299?term=AR-201&draw=2&rank=1)
Mechanisms of Action: Immunomodulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nestle
Company Location: VEVEY V8
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Egg Hypersensitivity|Environmental Hypersensitivity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AIME01 | P2 |
Terminated |
Egg Hypersensitivity|Environmental Hypersensitivity |
2020-12-16 |